Response Surface Optimization of Biocompatible Elastic Nanovesicles Loaded with Rosuvastatin Calcium: Enhanced Bioavailability and Anticancer Efficacy

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2020 May 13

PMID 32394333

Citations 10

Authors

Ibrahim Elsayed

Rania Moataz El-Dahmy

Soad Z El-Emam

Ahmed Hassen Elshafeey

Nabaweya Abdelaziz Abd El Gawad

Omaima Naim El-Gazayerly

Affiliations

Soon will be listed here.

Abstract

Statins are mainly used for the treatment of hyperlipidemia, but recently, their anticancer role was extremely investigated. The goal of this study was to statistically optimize novel elastic nanovesicles containing rosuvastatin calcium to improve its transdermal permeability, bioavailability, and anticancer effect. The elastic nanovesicles were composed of Tween® 80, cetyl alcohol, and clove oil. The nanodispersions were investigated for their entrapment efficiency, particle size, zeta potential, polydispersity index, and elasticity. The optimized elastic nanovesicular dispersion is composed of 20% cetyl alcohol, 53.47% Tween 80, and 26.53% clove oil. Carboxy methylcellulose was utilized to convert the optimized elastic nanovesicular dispersion into elastic nanovesicular gels. Both the optimized dispersion and the optimized gel (containing 2% w/v carboxymethylcellulose) were subjected to in vitro release study, scanning and transmission electron microscopy, histopathological evaluation, and ex vivo permeation. The cell viability assay of the optimized gel on MCF-7 and Hela cell lines showed significant antiproliferative and potent cytotoxic effects when compared to the drug gel. Moreover, the optimized gel accomplished a significant increase in rosuvastatin bioavailability upon comparison with the drug gel. The optimized gel could be considered as a promising nanocarrier for statins transdermal delivery to increase their systemic bioavailability and anticancer effect. Graphical abstract.

Citing Articles

Rosuvastatin Flexible Chitosomes: Development, In Vitro Evaluation and Enhancement of Anticancer Efficacy Against HepG2 and MCF7 Cell Lines.

Eleraky N, Hassan A, Soliman G, Al-Gayyar M, Safwat M AAPS PharmSciTech. 2024; 25(7):234.

PMID: 39375273 DOI: 10.1208/s12249-024-02957-w.

Transcending Traditional Treatment: The Therapeutical Potential of Nanovesicles for Transdermal Baclofen Delivery in Repeated Traumatic Brain Injury.

Sheta N, El-Gazar A, M Ragab G, A Essa M, Abdel-Haleem K, El-Dahmy R Adv Pharm Bull. 2024; 14(2):346-363.

PMID: 39206406 PMC: 11347745. DOI: 10.34172/apb.2024.031.

Injectable systems of chitosan in situ forming composite gel incorporating linezolid-loaded biodegradable nanoparticles for long-term treatment of bone infections.

Khaled Wassif R, Elkheshen S, Shamma R, Amer M, Elhelw R, El-Kayal M Drug Deliv Transl Res. 2023; 14(1):80-102.

PMID: 37542190 PMC: 10746766. DOI: 10.1007/s13346-023-01384-x.

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation.

El-Dahmy R, Elsayed I, Hussein J, Althubiti M, Almaimani R, El-Readi M Pharmaceutics. 2023; 15(4).

PMID: 37111569 PMC: 10146305. DOI: 10.3390/pharmaceutics15041083.

A novel oral medicated jelly for enhancement of etilefrine hydrochloride bioavailability: characterization and pharmacokinetic evaluation in healthy human volunteers.

Hassen Elshafeey A, El-Dahmy R Saudi Pharm J. 2022; 30(10):1435-1447.

PMID: 36387345 PMC: 9649358. DOI: 10.1016/j.jsps.2022.07.004.

References

Kapur N . Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther. 2007; 5(2):161-75. DOI: 10.1586/14779072.5.2.161. View

Ma Y, Li W, Xie Q . Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats. Pharmazie. 2013; 68(5):355-8. View

Chen C, Cheng C, Chen Y, Sue Y, Hsu Y, Tsai W . Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells. Eur J Pharmacol. 2013; 700(1-3):65-73. DOI: 10.1016/j.ejphar.2012.12.017. View

Miersch S, Sliskovic I, Raturi A, Mutus B . Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med. 2006; 42(2):270-9. DOI: 10.1016/j.freeradbiomed.2006.10.045. View

Resch U, Tatzber F, Budinsky A, Sinzinger H . Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol. 2006; 61(3):262-74. PMC: 1885020. DOI: 10.1111/j.1365-2125.2005.02568.x. View

Kata D, Foldesi I, Feher L, Hackler Jr L, Puskas L, Gulya K . Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells. Neuroscience. 2015; 314:47-63. DOI: 10.1016/j.neuroscience.2015.11.053. View

Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland J . Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res. 2008; 42(3):226-36. DOI: 10.1080/10715760701885380. View

Semenova A, Sergienko I, Masenko V, Gabrusenko S, Kukharchuk V, Belenkov I . [Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients]. Kardiologiia. 2008; 47(11):4-8. View

Hawk M, Cesen K, Siglin J, Stoner G, Ruch R . Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 1996; 109(1-2):217-22. DOI: 10.1016/s0304-3835(96)04465-5. View

10.

Mueck A, Seeger H, Wallwiener D . Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause. 2003; 10(4):332-6. DOI: 10.1097/01.GME.0000055485.06076.00. View

11.

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H . 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002; 122(2):308-17. DOI: 10.1053/gast.2002.31093. View

12.

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H . Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001; 61(12):4885-91. View

13.

Muller C, Bockhorn A, Klusmeier S, Kiehl M, Roeder C, Kalthoff H . Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol. 1998; 12(3):717-23. DOI: 10.3892/ijo.12.3.717. View

14.

Sumi S, Beauchamp R, Townsend Jr C, Uchida T, Murakami M, Rajaraman S . Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology. 1992; 103(3):982-9. DOI: 10.1016/0016-5085(92)90032-t. View

15.

Agarwal B, Bhendwal S, Halmos B, Moss S, Ramey W, Holt P . Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999; 5(8):2223-9. View

16.

Gizzo S, Quaranta M, Nardelli G, Noventa M . Lipophilic Statins as Anticancer Agents: Molecular Targeted Actions and Proposal in Advanced Gynaecological Malignancies. Curr Drug Targets. 2015; 16(10):1142-59. DOI: 10.2174/1389450116666150330113239. View

17.

Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y . Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer. 1994; 69(6):1015-20. PMC: 1969414. DOI: 10.1038/bjc.1994.199. View

18.

Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S . Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000; 271(3):688-92. DOI: 10.1006/bbrc.2000.2697. View

19.

Thurnher M, Nussbaumer O, Gruenbacher G . Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res. 2012; 18(13):3524-31. DOI: 10.1158/1078-0432.CCR-12-0489. View

20.

Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X . Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol. 2012; 45(3):745-52. DOI: 10.1016/j.biocel.2012.11.001. View